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ORIGINAL ARTICLE
An audit of the management of  
Chronic Obstructive Pulmonary Disease (COPD)  
patients in an outpatient setting: 
looking beyond the respiratory illness 
Malcolm Mintoff, Brendan Caruana Montaldo, Joelle Azzopardi 
BACKGROUND  
COPD is a major public health concern due to its associated morbidity and 
mortality, most of which is respiratory-related. However, a number 
of associated conditions exist, which independently contribute to morbidity 
and mortality, and therefore must be recognised and treated. The aim 
was to study the quality of management of outpatients with COPD, analyse 
whether associated comorbidities were being identified and treated, and if 
not, establish more effective ways of recognising missed opportunities. 
METHODS  
This retrospective study examined 37 out-patients with COPD seen by one 
respiratory firm in a Maltese tertiary centre. Out-patients were randomly 
selected between 2013 and 2015. The inclusion criterion was a post-
bronchodilator FEV1/FVC ratio of <0.7 measured during their most 
recent spirometry. Outcome measures included an accurate diagnosis of COPD; 
documentation of smoking history and smoking cessation; appropriate 
COPD treatment including inhaler technique and assessment of non-
adherence; appropriate prescription and usage of oxygen; referral to pulmonary 
rehabilitation; vaccination status; and consideration of comorbidities.  
RESULTS 
90% were male, mean age 68.5 years, and had all been correctly diagnosed with 
COPD, while 22% had a related comorbidity. The majority (81%) were ex-
smokers. Virtually all were on inhaled bronchodilators, with 60% also on an 
inhaled corticosteroid. The uptake of Influenza and Pneumococcal vaccination 
was at 62% and 54% respectively. Only 24% of patients were given physical 
activity advice or referral to a pulmonary rehabilitation programme. 
CONCLUSION 
The investigators analysed whether practices from one firm are in-keeping 
with the recommended international guidelines. A number of practices were 
adequate, while others needed improvement. In order to narrow this 
discrepancy, the investigators suggest creating a template for COPD patients to 
be used at future visits which includes the factors investigated. 
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INTRODUCTION 
Chronic Obstructive Pulmonary Disease 
(COPD) is a major worldwide public health 
concern due to its associated morbidity and 
mortality. In 2002, COPD was the 5th leading 
cause of death worldwide, and this is said to 
rise to the 3rd leading cause of death by 2030 
according to estimates by the World Health 
Organisation.1  
Although respiratory illness is the leading 
cause of morbidity and mortality in COPD2, 
there are a number of associated conditions 
which independently contribute to morbidity 
and mortality. Thus, these factors ought to be 
sought and recognised if they are to be 
treated, and hence have a favourable effect on 
decreasing morbidity and mortality in this 
group of patients.  
Despite the several treatments available to 
improve quality of life, decrease symptoms 
and reduce hospitalisation in COPD 
treatments, the only three modalities proven 
to decrease mortality are smoking-cessation 
programmes for patients with early disease, 
home oxygen treatment for persistent 
hypoxaemia, and lung volume reduction 
surgery (LVRS) for selected emphysema 
patients. 
The aim of this audit was to study the quality 
of management of outpatients with COPD; 
analyse whether the associated comorbidities 
were being identified and treated; ensure that 
suitable candidates for mortality-modifying 
treatments were being prescribed them; and if 
not, establish more effective ways of 
recognising missed opportunities.  
MATERIALS AND METHODS 
Participants and procedures 
This retrospective study examined thirty-
seven out-patients with COPD seen by one of 
four respiratory firms in a Maltese tertiary 
centre. Patients were randomly selected 
among those who visited the outpatient 
department over a 2-year period from 
September 2013 to September 2015. The 
inclusion criterion was a post-bronchodilator 
FEV1/FVC ratio of <0.7 measured during their 
most recent spirometry, as per diagnosis of 
COPD.3  
Outcome measures 
Various outcomes were considered, namely 
whether the diagnosis of COPD had been 
accurately made; whether a smoking history 
had been documented and thus smoking 
cessation implemented; whether treatment 
and inhaler technique were appropriate; and 
whether non-adherence was an issue. 
The study also analysed whether hypoxia was 
being checked for, and if so, whether 
supplemental oxygen had been prescribed and 
was being used appropriately. Where 
indicated, referral to Pulmonary Rehabilitation 
was audited. 
The investigators were also interested in 
whether comorbidities had been considered, 
namely Heart Failure, Polycythaemia and Sleep 
Disordered Breathing. Since influenza and 
pneumococcal vaccination are pivotal in COPD 
care, the audit considered vaccination data on 
the subjects. Lastly, records of participants 
were analysed for End of life care 
documentation. 
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Demographics and medical data 
Data was retrieved manually from individual 
patients’ clinical notes and electronically from 
iSOFT Clinical Manager (ICM). Spirometry 
testing was carried out by qualified spirometry 
nurses. Data was collected by two doctors not 
directly involved in the patients’ care.  
The data collected pertained to patient 
demographics, individual patient factors (e.g. 
weight, height, blood pressure (BP), 
respiratory symptoms, smoking status, and 
body mass index (BMI)), duration of care, 
spirometry results, smoking status, functional 
status, factors limiting self-care, treatment of 
COPD (e.g. medical treatment, treatment for 
smoking cessation and oxygen prescription), 
and influenza and pneumococcal vaccination 
status. 
RESULTS 
Demographics 
The large majority (90%) of patients studied 
were male, with ages ranging from 56-88 years, 
and a mean age of 68.5. The elderly (patients 
over 65 years of age) made up almost two-
thirds (64%) of the total patient population 
(Figure 1)  
Spirometry severity grade 
 All patients included in the study had been 
correctly diagnosed as COPD, with a post-
bronchodilator FEV1/FVC ratio of <0.7 as per 
diagnostic criterion for COPD.3 Most patients 
were in the moderate (FEV1 50-79%) or severe 
(FEV1 30-49% predicted) group, with a 
minority in the mild (FEV1 ≥80%) and very 
severe groups (FEV1 <30%)3 (Figure 2). 
Smoking status  
Although all patients were questioned about 
their smoking status at some point during their 
duration of care, documentation of smoking 
status within the previous 12 months was 
present in 79% of cases. 
The majority of the population (81%) were ex-
smokers, of which more than three quarters 
(76%) were former smokers and 5% recent  
Figure 1   Distribution of patients according to age groups 
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 quitters (quit less than 6 months previously). 
19% of patients were still smoking at the time 
of review (Figure 3). Of these (n=7), smoking 
cessation information was given to all patients 
at their most recent visit and during at least 1 
other outpatient appointment during the prior  
 12 months, such that 86% received brief 
advice, 57% were referred to a smoking 
cessation programme, and 29% were 
prescribed pharmacotherapy (nicotine 
replacement or Varenicline). Data on 1 patient 
was not available. 
Similar advice was also given to recent quitters 
in order to assist in preventing relapse. 
COPD treatment  
Virtually all study subjects were on inhaled 
short (SABA or SAMA) and long-acting 
bronchodilator (LABA or LAMA), with 60% also 
on an inhaled corticosteroid (ICS). A small 
proportion were on oral Theophylline, while 
none were on Leukotriene Receptor 
Antagonists, oral steroids (OCS) or LABA/ICS 
combinations (Figure 4). Inhaler technique was  
Figure 2    Distribution of patients according to severity of COPD based on FEV1 GOLD criteria 
Figure 3   Distribution of patients according to smoking status 
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documented to have been assessed in the 
previous 12 months in only 8% of the study 
population (Figure 5). 
Oxygen prescription 
Practically all patients (97%) had pulse 
oximetry documented at an out-patient visit 
within the previous 12 months. 5 patients 
(13.5%) had a saturation of 90% or less, and 
these were already on long-term (LTOT) or 
short burst oxygen therapy (SBOT). Arterial 
blood gases were not available for any of the 
patients within the last 12 months. Only in 1 
patient was LTOT being used unnecessarily, as 
the resting saturation on room air was 
documented at 96%. On review of all patients’ 
haemoglobin, none were noted to be 
polycythaemic (haematocrit >55%). There was 
no mention in the notes of cor pulmonale as an 
indication for LTOT. 
Figure 4    Percentage of patients on various COPD treatments 
 
Figure 5     Assessment of inhaler technique in previous 12months 
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Vaccinations 
The uptake of Influenza and Pneumococcal 
vaccination was relatively good, at 62% and 
54% respectively (Figure 6). Of those that were 
not vaccinated, the influenza and 
pneumococcal vaccines appear not to have 
been offered by the physician in 27% and 38% 
of patients respectively. The remainder 
refused it or had a medical reason for not 
receiving it, whilst in 5% of cases respectively, 
the information was not available. 
Physical activity advice/pulmonary 
rehabilitation 
Only 24% of patients were given advice 
regarding starting, increasing, or maintaining 
physical activity. This included brief advice or 
referral to a physical rehabilitation (PR) 
programme. The investigators did not make a 
distinction between physical activity advice 
and actual referral for PR.  
Comorbidities 
BP was documented on all patients within the 
previous 12 months, and was shown to be well 
controlled, with a mean of 129/73. Of the 
population studied, three COPD-related 
comorbidities were actively looked for: cor 
pulmonale, a raised haematocrit and sleep 
disordered breathing (SDB). 22% had some 
form of SDB, with none having cor pulmonale 
or a raised haematocrit.  
Functional status 
Patients’ functional status was categorised 
according to the Eastern Cooperative 
Oncology Group (ECOG) performance status4. 
Almost half (47%) were able to carry out 
physical work of a light intensity (ECOG 1), 
while just under a third (30%) were fully active 
(ECOG 0). A small proportion (8%) were 
“ambulatory and capable of all self-care but 
unable to carry out any work activities; up and 
Figure 6     Percentage of study patients receiving Influenza and Pneumococcal   
     vaccines respectively 
 
32
Malta Medical Journal     Volume 32 Issue 01 2020           
 
about more than 50% of waking hours’’ (ECOG 
2) while 14% were ‘‘capable of only limited 
self-care; confined to bed or chair more than 
50% of waking hours’’ (ECOG 3). None of the 
study patients were completely disabled 
(ECOG 4) (Figure 7). 
BMI 
All patients had a documented BMI from their 
spirometry records. Almost half of patients 
(43%) were noted to be overweight with a BMI 
of 25-29.9kg/m2. There were equal numbers of 
patients in the normal BMI range (18.5-
24.9kg/m2) and the obese range (30-
39.9kg/m2) (27% respectively). One patient 
was grossly underweight with a BMI of 
13.3kg/m2. 
Duration of care 
Three quarters of the patients (74%) had been 
followed up for more than twelve months prior 
to auditing. 
Factors limiting self-care 
Some factors which were considered to 
potentially hinder patient self-care were 
recorded, notably psychiatric illness or 
cognitive impairment (8%), non-adherence to 
smoking cessation or to COPD-related 
treatment (47%) and other medical conditions 
(8%). Financial factors were not readily                                  
available in this group of patients.                                              
DISCUSSION AND LIMITATIONS 
The number of participants in this study was 
small, and the view point was only that of one 
out of four firms. However, the aim was to 
analyse a cohort of COPD patients for what 
may be being missed in their follow-up, so as to 
create a proforma to be used on all future 
COPD patients, which may then be 
disseminated amongst all four respiratory 
firms. Data can subsequently be collected from 
all four firms so as to audit adherence with 
guidelines. 
All patients audited had been correctly 
diagnosed as having COPD, with an FEV1/FVC 
ratio on spirometry of <0.7. Investigators did 
not delve into the merits of whether patients 
were on the correct treatment depending on 
COPD Class according to COPD GOLD 
Guidelines 2014 (which have since been 
updated), as the CAT score was not recorded in 
the audit. However, results show that all 
patients were correctly on a short or long 
acting bronchodilator, and none were on 
Figure 7      Functional status of patients classified according to ECOG 
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inhaled corticosteroids alone. It was 
disappointing to note that in only 8% of cases 
was inhaler technique documented to have 
been checked in the previous year.  
Results show that in 21% of cases, a smoking 
history was not documented in the last 12 
months. However, the investigators did not go 
into the merits of whether this group of 
patients were smokers or ex-smokers. A 
postulation is that the physician may have 
flipped through the case notes and noted that 
the patient had quit smoking, and therefore 
not questioned the patient. However, this is a 
misgiving, as nicotine addiction can 
notoriously cause relapse in a former quitter. 
Another explanation may be of not 
documenting what is asked. 
One fifth of the study population was still 
smoking. Almost all received brief advice on 
quitting, just over half were referred to a 
smoking cessation programme, but less than 
one third were prescribed pharmacotherapy. 
These results are rather disappointing, as the 
evidence clearly shows that interventions that 
combine pharmacotherapy and behavioural 
support increase smoking cessation success 
compared to brief advice on quitting.5 
Hypoxia was actively searched for by pulse 
oximetry. The audit design did not consider 
ABGs, and therefore hypoxia was defined as a 
resting oximetry saturation of <88%. 
Furthermore, review of oxygen prescription 
was not considered, whereas the guidelines 
indicate that oxygen prescription should be 
reviewed at 60-90 days to assess continued 
indication and effectiveness.6 
Both influenza and pneumococcal vaccination 
uptake was relatively good in the population 
audited, in line with recommendations from 
the GOLD guidelines3. The GOLD guidelines 
distinguish between the 23-valent 
polysaccharide (PPSV23) and the 13-valent 
conjugate (PCV13) pneumococcal vaccines, 
stating that both PCV13 and PPSV23 should be 
given to all patients over the age of 65 years, 
whereas PPSV23 is also recommended for 
younger COPD patients with significant 
comorbid conditions including chronic heart or 
lung disease. The investigators in this audit did 
not differentiate between the 23-valent 
polysaccharide (PPSV23) and the 13-valent 
conjugate pneumococcal vaccination (PCV13). 
In the light of these guidelines, it is 
disappointing that vaccination was not offered 
to the study patients in a quarter to a third of 
cases.  
Pulmonary rehabilitation has been shown to 
be the most effective therapeutic strategy to 
improve shortness of breath, health status and 
exercise tolerance.7 
However, education about the benefits of 
exercise has not been shown to be effective, 
with an evidence Class C.8 Thus, grouping 
‘advice on exercise’ and ‘referral to pulmonary 
rehab’ in the same category was somewhat 
inaccurate in this audit. Even so, the uptake 
was poor, occurring in only a quarter of 
patients.  
The study population was not shown to be 
hypertensive. However, COPD patients are 
known to have associated comorbidities. Of 
the population studied, three COPD-related 
comorbidities were actively looked for: cor 
pulmonale, a raised haematocrit and sleep 
disordered breathing (SDB). Other 
comorbidities known to affect COPD patients 
(depression, osteoporosis, IHD) were not 
investigated.  
Despite COPD being known to be associated 
with mortality, whether independently or 
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through comorbidities, end of life discussion 
was not documented in the notes of any study 
subject within the last 12 months. 
CONCLUSION 
The audit attempted to investigate whether 
practices of one firm in a respiratory 
department of a tertiary hospital are in-
keeping with what is recommended by 
international guidelines, namely GOLD (Global 
Initiative for Chronic Obstructive Lung 
Disease). Whereas a number of practices were 
up to scratch, a number of others needed 
refining. In order to narrow this discrepancy, 
the investigators suggest creating a template 
for COPD patients to include all the factors 
that were investigated in the audit, so as to 
make it easier for the physician to ensure all 
aspects have been addressed during the 
encounter, and in as efficient a time as 
possible. Thus, this audit served as a pilot study 
to create a template for a much larger study 
that will serve to analyse whether guidelines 
are being adhered to, and will be disseminated 
within the whole respiratory department. 
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